Mr Nahas, how is Biopôle positioning itself in the Swiss innovation market and, looking ahead over the next five years, what specific goals are you pursuing?

Innovation is not only about great ideas, it is about bringing those ideas to the market, to the patients, or patients-to-be's beds. Biopôle positions its ecosystem all allong this value chain. From fostering early collaboration with our academic and clinical institutions, to offering entrepreneurs second-to-none infrastructure and innovation programmes to ultimately easing market access of those innovations through a dense and thorough network of corporate and strategic partners.

In the area of key technologies and disruptive models - which models do you see as having the greatest opportunities on the market?

I intimately believe that business models should be more and more geared towards impact. The idea is to rebalance the tension between a supply-driven and a demand-driven model, as well as to value products and services not through the marketing strength of their providers, but through the impact they have on users.

The conference FutureHealth calls for the discourse on a sustainable healthcare system, what targets are needed and by whom?

Actions are needed by all of us: citizens, politics, researchers, industrial partners and care providers. We collectively need to modestly acknowledge the crisis of our health system, the need to brake silos and to re-invent together new models.

Mr Nahas, what is the importance of Lausanne as a location in the national context and what are you particularly looking forward to at the conference?

The canton of Vaud is uniquely positioned nationally in the life sciences, with an unrivalled diversity ranging from biotech, pharma, healthtech and digital health to medtech. FutureHealth can really be a unique place to converge all national forces and brains around our health industry challenges, so that we collectively find the right solutions and models to embark into a paradigm-change journey.

Thank you Mr. Nahas for the Interview.